HSBC Securities Bumps Up Its "Buy" Rating On Merck -- Significantly. Sees $150 A Share Soon, On NYSE... [Power Alley]

This securities house was once known (for about a century and a quarter) as the Hong Kong Shanghai Banking Co. (note the half-tone/gray coat of arms/sheild in upper right quadrant of my graphic). It is over 160 years in operation, and its securities / research arm is quite well-respected around the globe. With Hong Kong now officially a PRC possession, it is good to see capitalistic (old British) entities doing quite well on the island.

All that said, I think the venerable house is right -- about Rahway. Mr. Davis has Merck firing on all cylinders -- and will likely have Keytruda as a juggernaut (on patenting tricks) well into the 2030s. Here's that -- (from an autobot / rag) but the graphic at right says it all:

. . .HSBC analyst Rajesh Kumar maintains Merck & Co., at a buy rating, and adjusts the target price from $120 to $150. . . .

Now you know. Onward, grinning into the cool sunshine. . . .

नमस्ते